Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

Abstract To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were define...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naihma Salum Fontana, K. I. Ibrahim, P. R. Bonazzi, F. Rossi, S. C. G. Almeida, F. M. Tengan, M. C. C. Brandileone, E. Abdala
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f7f273b780024cff9e34794e6eb012f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7f273b780024cff9e34794e6eb012f0
record_format	dspace
spelling	oai:doaj.org-article:f7f273b780024cff9e34794e6eb012f02021-12-02T13:30:09ZFluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients10.1038/s41598-021-81415-02045-2322https://doaj.org/article/f7f273b780024cff9e34794e6eb012f02021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81415-0https://doaj.org/toc/2045-2322Abstract To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.Naihma Salum FontanaK. I. IbrahimP. R. BonazziF. RossiS. C. G. AlmeidaF. M. TenganM. C. C. BrandileoneE. AbdalaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Naihma Salum Fontana K. I. Ibrahim P. R. Bonazzi F. Rossi S. C. G. Almeida F. M. Tengan M. C. C. Brandileone E. Abdala Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
description	Abstract To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.
format	article
author	Naihma Salum Fontana K. I. Ibrahim P. R. Bonazzi F. Rossi S. C. G. Almeida F. M. Tengan M. C. C. Brandileone E. Abdala
author_facet	Naihma Salum Fontana K. I. Ibrahim P. R. Bonazzi F. Rossi S. C. G. Almeida F. M. Tengan M. C. C. Brandileone E. Abdala
author_sort	Naihma Salum Fontana
title	Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
title_short	Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
title_full	Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
title_fullStr	Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
title_full_unstemmed	Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients
title_sort	fluoroquinolone treatment as a protective factor for 10-day mortality in streptococcus pneumoniae bacteremia in cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f7f273b780024cff9e34794e6eb012f0
work_keys_str_mv	AT naihmasalumfontana fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT kiibrahim fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT prbonazzi fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT frossi fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT scgalmeida fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT fmtengan fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT mccbrandileone fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients AT eabdala fluoroquinolonetreatmentasaprotectivefactorfor10daymortalityinstreptococcuspneumoniaebacteremiaincancerpatients
_version_	1718393009981095936

Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

Ejemplares similares